3.9 Article

Nasopharyngeal carriage of Streptococcus pneumoniae and pneumococcal urine antigen test in healthy elderly subjects

Journal

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
Volume 44, Issue 6, Pages 433-438

Publisher

INFORMA HEALTHCARE
DOI: 10.3109/00365548.2011.652162

Keywords

Streptococcus pneumoniae; carriage; colonization; elderly

Funding

  1. GlaxoSmithKline Biologicals
  2. GlaxoSmithKline
  3. Solvay Pharmaceuticals

Ask authors/readers for more resources

Background: Children frequently carry Streptococcus pneumoniae (pneumococcus) in their nasopharynx, even when healthy. Lower carriage rates have been reported in adults and only sparse data are available for the elderly. We sampled healthy elderly subjects for nasopharyngeal carriage to assess the prevalence of pneumococcal carriage using various assays. Methods: A deep nasopharyngeal swab sample was taken from 590 healthy elderly subjects aged >= 65 y. The samples were stored in STGG (skim milk-tryptone-glucose-glycerol) medium and cultured directly and after incubation in enrichment broth using routine identification methods. Real-time polymerase chain reaction (PCR) assays specific for pneumolysin and pneumococcal surface antigen A genes was performed on the same samples. Urine was also collected and assayed using the commercial Binax Streptococcus pneumoniae NOW urine antigen test. Results: The prevalence of pneumococcal carriage in healthy elderly persons was 1.5% for encapsulated pneumococci and 5.3% for all presumptive pneumococci. The use of the enrichment broth did not increase the yield of positives. PCR assays gave higher numbers of positives, but pneumolysin PCR in particular gave probable false-positive results. Only 1 urine antigen test was positive, and this was in a person not carrying pneumococcus. Conclusions: Nasopharyngeal carriage of pneumococci in the elderly was rare. Identification of presumptive pneumococci in culture requires further confirmation, e. g. by serotyping. The urine antigen test was not affected by concurrent carriage. Low carriage prevalence suggests that encapsulated pneumococci detected in a respiratory tract sample during sickness may be the true cause of disease, since contamination from asymptomatic nasopharyngeal carriage seems unlikely.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial

Hanna Rinta-Kokko, Arto A. Palmu, Esa Ruokokoski, Heta Nieminen, Marta Moreira, Lode Schuerman, Dorota Borys, Jukka Jokinen

Summary: This study assessed the indirect impact of a 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on pneumococcal disease. The results showed no clear indirect effects of PHiD-CV10 in an unvaccinated population, possibly due to low vaccination coverage and the implementation of a national vaccination program.

PLOS ONE (2022)

Article Medicine, Research & Experimental

A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to three-dose schedule of pneumococcal conjugate vaccination in rural Gambia: the PVS trial

Grant A. Mackenzie, Isaac Osei, Rasheed Salaudeen, Ilias Hossain, Benjamin Young, Ousman Secka, Umberto D'Alessandro, Arto A. Palmu, Jukka Jokinen, Jason Hinds, Stefan Flasche, Kim Mulholland, Cattram Nguyen, Brian Greenwood

Summary: This study aims to evaluate the feasibility and effectiveness of a reduced-dose schedule of pneumococcal conjugate vaccines (PCV) in middle- and low-income countries. The study uses a large cluster-randomised, non-inferiority, real-world trial design to compare an alternative "1 + 1" reduced-dose schedule with the standard "3 + 0" schedule, and evaluates the effects of both schedules using multiple endpoints.

TRIALS (2022)

Article Immunology

Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020-October 2021

Eero Poukka, Ulrike Baum, Arto A. Palmu, Toni O. Lehtonen, Heini Salo, Hanna Nohynek, Tuija Leino

Summary: Recently, the effectiveness of Covid-19 vaccines, especially against mild disease, has decreased due to the emergence of the Delta variant and waning protection. A register-based study in Finland found that the vaccine effectiveness of two-dose mRNA vaccine series against SARS-CoV-2 infection decreased from 82% to 53% after 6 months. Similar trends were observed for other vaccine series. Waning protection was not observed against Covid-19 hospitalization. These results inform decision-making regarding booster doses for healthcare workers.

VACCINE (2022)

Article Immunology

Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects

Anu Haveri, Anna Solastie, Nina Ekstrom, Pamela Osterlund, Hanna Nohynek, Tuomo Nieminen, Arto A. Palmu, Merit Melin

Summary: The emergence of the SARS-CoV-2 Omicron variant has raised concerns about neutralization escape and breakthrough infections. Researchers found that healthcare workers who received three doses of the vaccine had high levels of neutralizing antibodies, while the elderly had lower levels and some lacked antibodies against the Beta and Omicron variants. Previously infected subjects who received one mRNA vaccine dose had variable levels of cross-reactive neutralizing antibodies, but the levels against Omicron were barely detectable after one month.

EUROPEAN JOURNAL OF IMMUNOLOGY (2022)

Article Public, Environmental & Occupational Health

Hospital Contacts for Infectious Diseases Among Children in Denmark, Finland, Norway, and Sweden, 2008-2017

Lise Gehrt, Ida Laake, Helene Englund, Heta Nieminen, Christine Stabell Benn, Berit Feiring, Lill Trogstad, Arto A. Palmu, Signe Sorup

Summary: Comparing rates of childhood infectious disease hospitalisations across Denmark, Finland, Norway, and Sweden revealed significant differences in disease burden, organizational structures, and coding practices. Inpatient contacts requiring overnight stays reflected comparable levels of severe infections across countries. Boys and children under 2 years of age had the highest morbidity rates for childhood infectious diseases.

CLINICAL EPIDEMIOLOGY (2022)

Article Immunology

Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designs

Jussi Halme, Ritva K. Syrjanen, Ulrike Baum, Arto A. Palmu

Summary: This study compared different study designs for estimating influenza vaccine effectiveness and found that the register-based cohort design yielded results more consistent with the active test-negative design and produced more precise estimates.

VACCINE (2022)

Article Public, Environmental & Occupational Health

Trends in Antibiotic Use in Danish, Finnish, Norwegian and Swedish Children

Nils Skajaa, Lise Gehrt, Heta Nieminen, Ida Laake, Helene Englund, Ute Wolff Sonksen, Berit Feiring, Christine Stabell Benn, Lill Trogstad, Arto A. Palmu, Signe Sorup

Summary: There are differences in the use of antibiotics in children in four Northern European countries. However, the use of antibiotics in children has declined in all countries.

CLINICAL EPIDEMIOLOGY (2022)

Article Medicine, General & Internal

High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020-2021

Timothee Dub, Anna Solastie, Lotta Hagberg, Oona Liedes, Hanna Nohynek, Anu Haveri, Camilla Virta, Saimi Vara, Mervi Lasander, Nina Ekstrom, Pamela Osterlund, Katja Lind, Hanna Valtonen, Heidi Hemmila, Niina Ikonen, Timo Lukkarinen, Arto A. Palmu, Merit Melin

Summary: Household transmission studies found that other members in the household have a high risk of becoming infected following detection of a COVID-19 case. The early B-lineage SARS-CoV-2 antibodies persist for at least a year in most cases.

FRONTIERS IN MEDICINE (2022)

Article Medicine, General & Internal

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries

Jacob Dag Berild, Vilde Bergstad Larsen, Emilia Myrup Thiesson, Toni Lehtonen, Mari Grosland, Jon Helgeland, Jan Wolhlfahrt, Jorgen Vinslov Hansen, Arto A. Palmu, Anders Hviid

Summary: This study evaluated the association between AZD1222, BNT162b2, and mRNA-1273 vaccines and subsequent thromboembolic and thrombocytopenic events. The results showed an increased rate of hospital contacts for coagulation disorders and cerebrovascular disease, especially for thrombocytopenia and cerebral venous thrombosis, following vaccination with AZD1222.

JAMA NETWORK OPEN (2022)

Article Multidisciplinary Sciences

Time and labour costs of preventive health care, including vaccinations, in Finnish child health clinics

Heta Nieminen, Tuovi Hakulinen, Taneli Puumalainen, Paivi Siren, Arto A. Palmu

Summary: This study aimed to measure the time used by public health nurses and physicians in child health clinics in Finland for different tasks during visits, and evaluate the costs of preventive health care procedures. The study found that administering vaccines in Finnish child health clinics is relatively simple and inexpensive due to regular scheduled visits.

PLOS ONE (2022)

Article Immunology

Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland

J. Pekka Nuorti, Hanna Rinta-Kokko, Maija Toropainen, Lotta Siira, Hanna Nohynek, Arto A. Palmu

Summary: The study showed significant indirect effects of PCV10 on vaccine-serotype IPD and overall IPD in adults. Non-vaccine IPD incidence stabilized after 5 years of infant PCV10 introduction, with non-vaccine IPD accounting for nearly 90% of overall IPD. Older adults still face a substantial burden of pneumococcal disease.

VACCINE (2022)

Article Immunology

Corresponding author at: .

Heta Nieminen, Mika Lahdenkari, Ritva K. Syrjanen, Hanna Nohynek, Esa Ruokokoski, Arto A. Palmu

Summary: A natural experiment in Finland showed that the BCG vaccine administered in the national vaccination program had non-specific effects, reducing the incidence of hospital-diagnosed infections, particularly respiratory infections, during the first three months of life. However, in the follow-up from four to twelve months, BCG-vaccinated children had slightly higher infection rates compared to the non-vaccinated children.

VACCINE (2022)

Article Infectious Diseases

High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron

Ulrike Baum, Eero Poukka, Tuija Leino, Terhi Kilpi, Hanna Nohynek, Arto A. Palmu

Summary: This study found that vaccine effectiveness against severe COVID-19 is high among the elderly. The effectiveness slightly waned after two doses, but a third dose restored the protection. Furthermore, the vaccine effectiveness against severe COVID-19 remained high even after the emergence of the Omicron variant.

BMC INFECTIOUS DISEASES (2022)

Article Medicine, Research & Experimental

Pneumococcal vaccine schedules (PVS) study: a cluster-randomised, non-inferiority trial of an alternative versus standard schedule for pneumococcal conjugate vaccination-statistical analysis plan

Grant A. A. Mackenzie, Arto A. A. Palmu, Jukka Jokinen, Isaac Osei, Stefan Flasche, Brian Greenwood, Kim Mulholland, Cattram Nguyen

Summary: The effectiveness of universal immunisation with pneumococcal conjugate vaccine (PCV) has been evident in many countries. However, the cost of PCV limits its global impact. This study aims to compare the effectiveness of an alternative vaccine schedule with a lower cost to the standard schedule, and improve the sustainability of PCV in low-income countries.

TRIALS (2022)

Article Immunology

Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022

Anna Solastie, Tuomo Nieminen, Nina Ekstrom, Hanna Nohynek, Lasse Lehtonen, Arto A. Palmu, Merit Melin

Summary: Studying the prevalence of SARS-CoV-2 specific antibodies allows for assessing the impact of containment measures and vaccinations. In Finland, N-IgG seroprevalence remained low until 2021 and increased rapidly after the emergence of the Omicron variant. Seroprevalence was highest in the youngest age groups from 2022 onwards. By the end of 2022, it was estimated that 51% of the Finnish population had antibody-mediated hybrid immunity.

EMERGING MICROBES & INFECTIONS (2023)

No Data Available